Neuroectodermal Tumors, Primitive, Peripheral clinical trials
The registry lists 80 studies for Neuroectodermal Tumors, Primitive, Peripheral across more than 10 countries. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 57
- Active, not recruiting
- 10
- Terminated
- 7
- Withdrawn
- 4
- Recruiting
- 2
Phase
- Phase 2
- 47
- Phase 1
- 25
- Phase 3
- 1
- Early Phase 1
- 1
Where
- United States
- 70
- Puerto Rico
- 15
- Canada
- 11
- Australia
- 7
- France
- 5
- Spain
- 4
Who runs them
National Cancer Institute (NCI) (32) · Children's Oncology Group (10) · City of Hope Medical Center (3) · St. Jude Children's Research Hospital (3) · Dana-Farber Cancer Institute (2) · Istituto Ortopedico Rizzoli (2) · Eli Lilly and Company (2) · Gradalis, Inc. (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 80 — search for more.
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 13 countries
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingNCT04901702Phase 1/22 countries
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03210714Phase 22 countries
- Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 22 countries
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsCompletedNCT01946529Phase 21 country
- Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 23 countries
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 24 countries
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 22 countries
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 24 countries
- Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 23 countries
- Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 22 countries
- Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARDActive, not recruitingNCT06068075Not applicable1 country
- Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 22 countries
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 22 countries
- Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 22 countries
- First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)CompletedNCT03011528Phase 21 country
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young AdultsTerminatedNCT04530487Phase 21 country
- Quality of Life of Patients With Bone Tumor of the Lower Limbs Treated With Salvage SurgeryCompletedNCT057723121 country
- Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid TumorCompletedNCT00638898Phase 11 country
- SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for SarcomaActive, not recruitingNCT03778996Phase 21 country
- TK216 in Patients With Relapsed or Refractory Ewing SarcomaTerminatedNCT02657005Phase 1/21 country
- Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 22 countries
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 22 countries
- Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid TumorsCompletedNCT01661400Phase 11 country
- Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's SarcomaCompletedNCT02736565Phase 11 country
- Stereotactic Radiosurgery in Treating Patients With Brain TumorsCompletedNCT00019578Phase 11 country
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/22 countries
- Collecting and Storing Biological Samples From Patients With Ewing SarcomaCompletedNCT008999906 countries
- The Prognostic Value of Serum Biomarkers in Ewing's SarcomaCompletedNCT051003681 country
- A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and TemozolomideTerminatedNCT03495921Phase 31 country
- Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing SarcomaCompletedNCT03275818Phase 21 country
- Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of ChemotherapyCompletedNCT01222767Phase 23 countries
- Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal TumorsCompletedNCT01217437Phase 25 countries
- Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms TumorsTerminatedNCT02581384Phase 1/21 country
- High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicable1 country
- Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent MalignanciesCompletedNCT02116777Phase 1/21 country
- Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A AntibodyCompletedNCT021594431 country
- Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01154816Phase 22 countries
- Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/27 countries
- HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid TumorsWithdrawnNCT02557854Phase 11 country
- Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 22 countries
- Trial of Dasatinib in Advanced SarcomasCompletedNCT00464620Phase 21 country
- Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade GliomaCompletedNCT01977677Phase 1/21 country
- Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of TumorsCompletedNCT00070109Phase 22 countries
- A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)TerminatedNCT00617890Phase 2
- Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/21 country
- Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid TumorsWithdrawnNCT02011126Phase 2
- A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaCompletedNCT00668148Phase 27 countries
- Yoga Therapy in Treating Patients With Malignant Brain TumorsTerminatedNCT01234805Not applicable1 country
- Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or NeuroblastomaCompletedNCT00923351Phase 1/21 country